From molecule to business

Plaats: Sanadome, Nijmegen
Tijd: van 13.00 – 19.30 uur

Hoe vertaal je de ideeën die je hebt naar een succesvol bedrijf binnen de life sciences? Hoe ga je van idee naar BV? Welke vraagstukken kom je tegen als je bedrijf groeiende is? Wat moet iemand die onderneemt binnen de life sciences in huis hebben…?

Health Valley organiseert voor life sciences professionals een bijeenkomst waarin bovenstaande vragen aan de orde komen.
SMB zal bij monde van John Schalken haar rol toelichten op de Red Med Tech Highway.

Voor het programma, aanmelding en meer informatie zie website Health Valley

New vice president toxicology Khondrion

Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, has appointed toxicology expert Dr. Sjeng Horbach as Vice President Toxicology. Sjeng will be responsible for expanding Khondrion’s activities in mitochondrial drug development by supporting the strong growth of our company.

Commenting on his appointment, Mr. Horbach said: “Khondrion has groundbreaking science, a highly motivated workforce and a strong commitment to develop a cure for patients with mitochondrial disease. This is a key-time to be joining the Khondrion team. As the mitochondrial drug development is developing as planned there are many toxicology issues that need to be addressed in order before new drugs reach the patients that need them. I look forward to join the passionate Khondrion team”.
Khondrion’s CEO, Jan Smeitink, commented: “We are very pleased that Sjeng is joining our team as Vice President Toxicology. His expertise will definitely drive our product development forward. Patients with mitochondrial disease have a progressive disease course and many of them pass away at an early age. Our main goal is to end this.”

Sjeng Horbach joins Khondrion from Merck Sharp & Dohme (MSD), where he had, before closure of the research site in Oss the position of Director Toxicology.

About Khondrion
Khondrion is an innovative Dutch biopharmaceutical mitochondrial medicine company focusing on developing small molecule therapeutics for mitochondrial diseases. The potential of several lead compounds to serve as new treatment modalities for mitochondrial disease are currently explored. Thanks to its strategic partnership with the Nijmegen Centre for Mitochondrial Disorders (
) of the Radboud University Nijmegen Medical Centre, Khondrion has access to all mitochondrial tools, technologies and expertise. Besides, Khondrion has established collaborations with university research groups around the world as well as small, medium and large enterprises. Khondrion is a privately held biopharmaceutical company, among others supported by the Dutch Foundations Energy4All, Rare Disease and the US based Mitochondrial Medicine Foundation. For more information, please visit